Omeros (OMER) shares closed more than 150% higher on Oct. 15 after the biotechnology firm announced a licensing agreement with the Danish pharmaceutical giant Novo Nordisk (NVO). The deal includes $340 million in upfront and near-term milestone payments, along with additional potential deployment and commercial milestones, plus tiered royalties on net sales. More News from Barchart In total, the transaction is worth up to$2.1 billion. At the time of writing, OMER stock is trading up more than 260% from ...